Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd specializes in the development and manufacturing of generic and specialty pharmaceuticals, primarily focusing on the Chinese market. The company has a competitive edge through its established distribution networks and a diverse product portfolio that includes over 200 drug formulations.
The company generates revenue through the sale of generic and specialty drugs, leveraging its strong relationships with hospitals and pharmacies across China. Its competitive advantages include a robust R&D pipeline, regulatory compliance expertise, and cost-effective manufacturing processes that allow for competitive pricing.
Regulatory approvals for new drug formulations
Changes in healthcare policy affecting drug pricing
Market share gains in the generic drug segment
Fluctuations in raw material costs impacting margins
Regulatory changes in drug approval processes
Intellectual property challenges from competitors
Increased competition from domestic and international generic manufacturers
Potential for price erosion in the generic drug market
Low liquidity as indicated by free cash flow of $0.0B
Dependency on continued access to credit markets for operational flexibility
moderate - the pharmaceutical industry is somewhat insulated from economic downturns, but demand can be affected by consumer spending on healthcare.
Minimal impact as the company has low debt levels (Debt/Equity of 0.09), but rising rates could affect consumer spending on healthcare products.
minimal
value - the company’s low debt and stable cash flows may appeal to value investors looking for stability in the healthcare sector.
moderate - the stock has shown fluctuations with a 1-year return of -5.7%, indicating some volatility.